Overview
Study of MRA in Patients With Rheumatoid Arthritis (RA)
Status:
Completed
Completed
Trial end date:
2009-06-01
2009-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is an open-label, extension, Phase II study to evaluate the long-term safety and efficacy of MRA in Patients with RA who were participated in Study MRA009JP.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Chugai Pharmaceutical
Criteria
Inclusion Criteria:- Patients administered MRA more than 2 times in preceding study, MRA009JP, and
evaluated the efficacy and the safety.
- Patients confirmed to have shown the safety in the preceding study.
Exclusion Criteria:
- Patients with Class IV Steinbrocker functional activity at evaluation within 4 weeks
before treatment with the study drug
- Patients who received any of the following treatments between the start of preceding
study and the registration of this study.
1. Plasma exchange therapy
2. Surgical treatment (e.g., operation)